N/A
Completed N=242
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
Carcinoma, Renal Cell · Lymphoma, Mantle-Cell
Source: ClinicalTrials.gov NCT01367457 ↗
Enrolled (actual)
242
Serious AEs
11.6%
Results posted
Apr 2016
Primary outcomePrimary: Progression-free Survival (PFS) — 4.04; 7.467; 13.233 months
Summary
The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival (PFS) |
4.04; 7.467; 13.233 | — |
| PRIMARY Percentage of Participants With Objective Response |
0.5; 34.8; 30.8; 14.3; 17.4; 50.0 | — |
| PRIMARY Duration of Response (DOR) |
13.21; 7.28; 8.82 | — |
| PRIMARY Overall Survival (OS) |
10.81; 19.233; 18.667 | — |
| PRIMARY Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) |
145; 19; 16; 18; 3; 7 | — |
Eligibility Criteria
Inclusion Criteria
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
Exclusion Criteria
Patients that do not have a minimum (pre-specified) of data in their clinical record.
Data sourced from ClinicalTrials.gov (NCT01367457). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.